Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jan 8;18(1):116. doi: 10.3390/ijms18010116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

PET scans of C57Bl/6j mice administered: (a) [⁸⁹Zr(oxalate)₄]⁴⁻; (b) ⁸⁹Zr-THP-mal-trastuzumab; and (c) ⁸⁹Zr-DFO-mal-trastuzumab. For the animal administered [⁸⁹Zr(ox)₄]⁴⁻ 98% of the injected dose remains 4 h post-injection, and is associated predominantly with the skeleton. For the animal administered ⁸⁹Zr-THP-mal-trastuzumab, the skeleton is clearly visible from three days post-injection, indicative of dissociation of ⁸⁹Zr⁴⁺ from THP-mal-trastuzumab over time. This is in marked contrast to the animal administered ⁸⁹Zr-DFO-trastuzumab, where the blood pool remains visible out to seven days post-injection. Reprinted with permission under a Creative Commons Attribution (CC-BY) License from Ma, M.T.; et al. Tripodal tris(hydroxypyridinone) ligands for immunoconjugate PET imaging with ⁸⁹Zr⁴⁺: comparison with desferrioxamine-B. Dalton Trans. 2015, 44, 4884–4900. Copyright Royal Society of Chemistry.